<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Hematological VitroScreen

May 1st - July 12th, 2024

The industry's largest blood malignancy screen, featuring highly characterized, clinically relevant models of ALL, AML, CLL, MCL, MM, and MDS



Enroll in Champions' industry-leading hematologic model screening platform until July 12th, 2024

Gain access to the largest biobank of extremely difficult-to-source and never passaged before primary hematological malignancies models, including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM), and Myelodysplastic Syndrome (MDS) for robust ex vivo investigations. These clinically relevant models offer heterogenous responses, mirroring those observed in patients, ensuring dependable outcomes crucial for advancing your drug discovery efforts with confidence.

Hematological Vitro Screen offers:

  • Comprehensive model characterization (stored in Lumin) with:
            ✅Robust clinical data annotations
            ✅NGS (RNAseq and WES) analysis
            ✅Flow Cytometry
            ✅Proteomics and phospho-proteomics
  • Largest biobank of difficult-to-source and never passaged (primary) models in the industry.
  • Carefully curated models with ex vivo explants and in vivo engraftment capabilities.
  • Several endpoint data options available including western blot, flow cytometry, 4D proteomics and more to maximize insights for our partners.
  • 50% off of a Standard of Care agent arm (selected by Champions)
  • No minimum number of models to enroll and you have the ability to select the models you want to screen.
Choose a Model from the List Below to Access In-Depth Clinical Data
Hematologic vitro screen May 2024

Figure 1: The Ex Vivo Hematologic Assay workflow outlines the typical study durations for different cancer types and the range of available endpoint data options.

Endpoint options Hematologic screen May 2024

Figure 2: The table displays a variety of endpoint options for different cancer types screened, including AML and other malignancies, utilizing diverse platforms to deliver comparative and reproducible results.

Example Responses to Standard of Care Drugs
Acute Myeloid Leukemia CTG-3950 - Standard of Care


A. CTG-3950 (AML) model responds well  to cytarabine and only responds moderately to venetoclax

Acute Lymphoblastic Leukemia CTG-2406 - Standard of Care


B. CTG-2406 (ALL) model is responsive to doxorubicin, but not very responsive to cytarabine.

Chronic Lymphocytic Leukemia CTG-3945 - Standard of Care
C. CTG-3945 (CLL) models responds well to both ibrutinib and chlorambucil.
Mantle Cell Leukemia CTG-4085 - Standard of Care
D. CTG-4085 (MCL) model responses well to bortezomid and responds in moderation to venetoclax.  
Chronic Myelomonocytic Leukemia CTG-4200 - Standard of Care
E. CTG-4200 (CMML)  model responds to cytarabine and is resistant to venetoclax.
Endpoint Data Examples 

Comet Assay

Comet Assay_April 2023 For Landing page

Figure 3: AML model CTG-3950 shows extensive DNA damage (green tail) after treatment with cisplatin 1μM. Lower doses of cisplatin did not significantly increase DNA damage compared to negative control (0.1% DMSO).

Colony Forming Unit Assay

AML model CTG-2456 Colony forming assay

Figure 4: AML model CTG-2456 shows a prevalence of CFU-GM. Treatment with Cytarabine at doses ≥10nM reduces the formation of these units. ATRA and 10% DMSO were used as positive controls.

Enroll Today in Champions' Hematological VitroScreen